Windlas Biotech Limited IPO Detail
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Competitive strengths
- Leading market player in the domestic pharmaceutical formulation CDMO segment.
- Strong focus on the chronic therapeutic category.
- state-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
- Professional and experienced Promoters and a senior management team.
- An innovative product portfolio of complex generic products.
- Robust financial performance track record.
Company Promoters
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt TrustIPO Details
| IPO Opening Date | Aug 04, 2021 |
| IPO Closing Date | Aug 06, 2021 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹5 per equity share |
| IPO Price | ₹448 - 460 per equity share |
| Market Lot | 30 Shares |
| Min Order Quantity | 30 Shares |
| Listing At | BSE, NSE |
| Issue Size | ₹401.54 Cr |
| Fresh Issue | 5,142,067 Eq Shares of ₹5 (aggregating up to ₹[.] Cr) |
| Offer for Sale | 5,142,067 Eq Shares of ₹5 (aggregating up to ₹[.] Cr) |
| Retail Portion | 35% |
IPO Subscription (Bidding Detail)
| AS On | QIB | SHNI | BHNI | NII | RII | TOTAL |
|---|---|---|---|---|---|---|
| Day 1 | 0.00x | - | - | 0.34x | 6.12x | 3.15x |
| Day 2 | 0.04x | - | - | 1.11x | 13.40x | 6.99x |
| Day 3 | 24.40x | - | - | 15.73x | 24.22x | 22.44x |
IPO Tentative Timetable
The Windlas Biotech Limited IPO open date is Aug 04, 2021, and the close date is Aug 06, 2021. The issue may list on Aug 16, 2021.
| IPO Open Date | Aug 04, 2021 |
| IPO Close Date | Aug 06, 2021 |
| Basis of Allotment Date | Aug 11, 2021 |
| Initiation of Refunds | Aug 12, 2021 |
| Credit of Shares to Demat Account | Aug 13, 2021 |
| IPO Listing Date | Aug 16, 2021 |
IPO Lot Size
The Windlas Biotech Limited IPO market lot size is 30 shares. A retail-individual investor can apply for up to 14 lots (420 shares or ₹193200).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 30 | ₹13800 |
| Maximum | 14 | 420 | ₹193200 |
IPO Promoter Holding
| Pre Issue Share Holding | 78% |
| Post Issue Share Holding |
Company Financials:
For the year/period ended (₹ in Crs)
| Financial Year | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Dec-20 | 315.88 | 323.09 | 9.67 |
| 31-Mar-20 | 338.49 | 331.33 | 16.21 |
| 31-Mar-19 | 298.18 | 311.52 | 63.82 |
| 31-Mar-18 | 289.88 | 356.57 | 11.20 |
Objects of the Issue:
- To purchase equipment required for capacity expansion of our existing facility at Dehradun Plant IV.
- To finance incremental working capital requirements of the company.
- Repayment/prepayment of company's borrowings.
- General corporate purposes.
